Collectively, these findings underscore the importance of understanding IL-6’s tissue-specific roles and suggest that while IL-6R antagonists hold promises for modulating immune-driven fibrotic pathways, their translation into therapies for liver fibrosis must be approached with caution. This evidence concerns the gene IL6R and Hepatic fibrosis.